January 9, 2007-- Amphora Discovery Corporation sold an early-stage oncology program to Genentech; AtheroGenics fell after dealying information on its coronary artery disease drug until late in the first quarter; Biogen Idec began a Phase III trial of a new MS drug; Xoma began a Phase I/II trial of Neuprex in patients who receive stem cell transplants; InterMune received a $10 million milestone after delivering supply of its hepatitis C virus drug candidate; Alnylam in-licensed liposomal delivery technology from Inex; BioWa and Medarex received an FDA go-ahead to begin trials of a new lymphoma drug; and the Medicines Company announced Cleviprex met its endpoints in three Phase III safety trials. The Centient Biotech 200™ closed 2 points higher at 3990, an increase of .06%. More details...
